New triple therapy aims to outsmart Hard-to-Treat colorectal cancer
NCT ID NCT06497985
First seen Apr 05, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study tests a new combination of three drugs (tucidinostat, sintilimab, and bevacizumab) against a standard single drug (fruquintinib) in people with a common type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combination helps patients live longer. About 430 adults aged 18 to 75 with MSS/pMMR colorectal cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rui-Hua Xu
RECRUITINGGuangzhou, Guangdong, 510050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.